4basebio (LON:4BB) Stock Price Down 2.1% – What’s Next?

Shares of 4basebio PLC (LON:4BB) fell 2.1% during trading on Thursday . The stock traded as low as GBX 1,185 ($14.67) and last traded at GBX 1,185 ($14.67). 3,034 shares were traded during trading, a decline of 31% from the average session volume of 4,379 shares. The stock had previously closed at GBX 1,210 ($14.98).

4basebio Stock Performance

The stock’s 50-day moving average price is GBX 1,251.16 and its 200 day moving average price is GBX 1,376.71. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The company has a market cap of £151.80 million, a P/E ratio of -1,519.23 and a beta of 1.09.

Insider Buying and Selling

In other 4basebio news, insider Heikki Lanckriet bought 46,500 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The stock was purchased at an average price of GBX 1,325 ($16.40) per share, for a total transaction of £616,125 ($762,625.32). Insiders own 68.44% of the company’s stock.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.